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Available online 24 October 2016Many enzyme replacement therapies (ERTs) for lysosomal storage disorders use the cell-surface cation-
independent mannose-6 phosphate receptor (CI-M6PR) to deliver ERTs to the lysosome. However, neutralizing
antibodies (NAb)may interfere with this process. We previously reported that most individuals with Morquio A
who received elosulfase alfa in the phase 3 MOR-004 trial tested positive for NAbs capable of interfering with
binding to CI-M6PR ectodomain in an ELISA-based assay. However, no correlationwas detected betweenNAb oc-
currence and clinical efﬁcacy or pharmacodynamics. To quantify and better characterize the impact of NAbs, we
developed a functional cell-based ﬂow cytometry assay with a titer step that detects antibodies capable of inter-
feringwith elosulfase alfa uptake. Serum samples collected during theMOR-004 trial were tested and titers were
determined. Consistentwith earlierﬁndings onNAbpositivity, no correlationswere observed betweenNAb titers
and the clinical outcomes of elosulfase alfa-treated individuals with Morquio A.
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The mucopolysaccharidosis (MPS) diseases are a group of lyso-
somal storage disease caused by a deﬁciency of enzymes catalyzing
the stepwise degradation of glycosaminoglycans (GAGs). Individuals
with the autosomal recessive MPS disorder Morquio A syndrome
(mucopolysaccharidosis IVA, MPS IVA; OMIM 253000) have mutations
in the gene encoding the enzyme N-acetylgalactosamine-6-sulfatase
(GALNS; EC 3.1.6.4), resulting in deﬁcient GALNS enzyme activity and
accumulation of the GAGs keratan sulfate and chondroitin-6-sulfate in
the lysosomes of individuals with Morquio A syndrome. Although
symptoms can vary, Morquio A syndrome generally manifests as a pro-
gressive disorder with multiple organ and tissue involvement that is
characterized by restricted growth, severe skeletal malformations,ntibody; LSD, lysosomal storage
lacement therapies; rhGALNS,
; 6MWT, six minute walk test;
ventilation; uKS, urine keratan
pendent mannose-6-phosphate
;HQC, high quality control; NPS,
antibody positive control;MRD,
MFI,medianﬂuorescence inten-
TCP, titer cut point.
, CA 94901, United States.
. This is an open access article undercorneal opacity, restricted hearing, and premature death (Harmatz
et al., 2013; Hendriksz et al., 2013). Elosulfase alfa (Vimizim®;
rhGALNS; BMN 110) is a US Food and Drug Administration-approved
enzyme replacement therapy (ERT) for the treatment ofMorquio A syn-
drome. The previously reported results of a pivotal phase 3 clinical trial,
MOR-004, which demonstrated that elosulfase alfa administered either
weekly (QW) or every other week (QOW) for 24 weeks to individuals
with Morquio A syndrome had an acceptable safety proﬁle, and QW
dosing signiﬁcantly improved 6-min walk test (6MWT) distance, 3-
min stair climb test (3MSCT), and respiratory function (maximum vol-
untary ventilation [MVV]). In addition, the high urine levels of the phar-
macodynamicmarker keratan sulfate (uKS) characteristic of individuals
with Morquio A syndrome were signiﬁcantly reduced with elosulfase
alfa treatment (Hendriksz et al., 2014).
A number of ERTs for the treatment of various lysosomal storage dis-
orders, including elosulfase alfa, contain mannose-6-phosphate (M6P)
moieties and depend on the CI-M6PR transmembrane receptor for in-
ternalization and trafﬁcking to the lysosome. Biological therapies can
elicit an immune response, resulting in the generation of antidrug
antibodies capable of binding to the drug product and, in some cases,
interfering with receptor binding on the target cell. Furthermore,
these antibodies may negatively impact efﬁcacy (Brooks et al., 2003;
Desnick and Schuchman, 2012; Banugaria et al., 2011). The MOR-004
study showed that all individuals treated with elosulfase alfa developed
drug-speciﬁc total antibodies (TAb). A subset of drug-speciﬁc antibodiesthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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of interfering with CI-M6PR binding, positivity for which was revealed
using an ELISA-based in vitro assay (CI-M6PR binding assay). Although
elosulfase alfa-speciﬁc antibody development was universal among
treated individuals in the MOR-004 study, no relationship was detected
between TAb titers or NAb positivity and themagnitude of physical im-
provements or reductions in uKS levels (Schweighardt et al., 2015).
In this study, we describe a novel, cell-based ﬂow cytometrymethod
for identifying and titering NAbs capable of inhibiting cellular uptake
(functional NAb assay) to determine if this measurement might be
more clinically meaningful than measuring inhibition of receptor bind-
ing, as was measured in the original study. Serum samples were co-
incubated with Alexa488-labeled rhGALNS, and ﬂow cytometry was
used to detect interference of drug internalization by human Jurkat
cells, which express transmembrane CI-M6PR on the cell surface.
Assay sensitivity, precision, speciﬁcity, selectivity, as well as drug toler-
ance were determined, and cut points were calculated to set thresholds
for assessing positive samples. In support of our previous ﬁndings that
NAb positivity had no correlation with clinical outcomes or pharmaco-
dynamic effects (Schweighardt et al., 2015), testing of MOR-004
samples with the functional NAb assay demonstrated that NAb titer is
not correlated with efﬁcacy outcomes or pharmacodynamic effects of
elosulfase alfa in individuals with Morquio A syndrome.
2. Materials and methods
2.1. Clinical study design
MOR-004 (NCT01275066)was a phase 3, randomized, double-blind,
placebo-controlled study designed to assess the safety and efﬁcacy of
elosulfase alfa administered at 2.0 mg/kg QW or QOW in individuals
with Morquio A syndrome. The study protocol was approved at each
participating clinical site by an institutional review board, independent
ethics committee, or research ethics board. Prior to entering the study,
each participant or his/her legally authorized representative provided
written informed consent. The assigned treatmentwas blinded to inves-
tigators, site personnel, and patients until the completion of the ﬁnal
analysis. Of the 176 study participants, 59 received placebo, 58 received
elosulfase alfa 2.0 mg/kg QW, and 59 received elosulfase alfa 2.0 mg/kg
QOW. The MOR-004 study design, inclusion criteria, and endpoints
were reported previously (Hendriksz et al., 2014).
2.2. Immunogenicity testing
Serum samples were collected from all individuals for immunoge-
nicity testing prior to dose administration at baseline, weeks 2 and 4,
and every 4 weeks thereafter (or within 1 week of the early-
termination visit). Detailed methods for sample preparation and theCells Single Cells 
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Fig. 1.Assay platformﬂow cytometry gating strategy. Jurkat cellswere separated from all events
channels. Cell doublets were then removed by gating on single cells using the FSC area (FSC-A)
cells not labeled with LIVE/DEAD cell stain. Median ﬂuorescence intensity (MFI) of Alexa488
without Alexa488-rhGALNS (red and blue histograms, respectively) are shown.CI-M6PR binding assay were reported previously (Schweighardt et al.,
2015). In brief, TAb titers were determined by a validated bridging
electrochemiluminescence (ECL) assay, and positivity for NAb was de-
termined by a validated in vitro assay that assessed interference of
elosulfase alfa binding to CI-M6PR immobilized on an ELISA plate.
2.3. Functional NAb assay
Alexa488 was conjugated to rhGALNS (BioMarin Pharmaceutical
Inc.) using anAlexa Fluor 488 Protein LabelingKit (Molecular Probes) ac-
cording to the manufacturer's protocol. Alexa488-conjugated rhGALNS
had an average labeling ratio of 1.75 mol of Alexa488 per mole of
rhGALNS as determined by absorbance at 494 nm. Quality controls,
serum samples, immunodepleted samples for conﬁrmation, or 3-fold se-
rially diluted serum samples for titration were diluted 1:2.5 in serum-
free RPMI-1640 with high glucose, L-glutamine, and HEPES (ATCC) and
incubated with 0.4 μg/mL Alexa488-conjugated rhGALNS in duplicate
wells overnight at 4 °C. Samples were then added to Jurkat cells (clone
E6-1, ATCC) plated at 7.5 × 104 cells per well in 96-well round bottom
plates and incubated for 3 h at 37 °C and 5% CO2. Cells were washed 3
times in PBS after centrifugation at 310 ×g, stained with 1:1000 LIVE/
DEADFixable RedDead Cell Stain Kit (Molecular Probes) for 15min, cen-
trifuged, and ﬁxed with 1% paraformaldehyde for 10 to 15 min at room
temperature or up to 72 h at 2 °C to 8 °C. Fixed cells were analyzed for
ﬂuorescence on a BD LSRII ﬂow cytometer using BD FACSDiva software
(BD Biosciences). Dead cells were excluded from the analysis, and ap-
proximately 10,000 events were recorded. Uptake of Alexa488-
conjugated rhGALNSwas reported as mean of duplicatemedian ﬂuores-
cence intensity (MFI) measurements from adjacent wells.
2.4. Conﬁrmation assay sample preparation
Samples that met the threshold for NAb positivity in the screening
assay were veriﬁed using a conﬁrmation assay. Brieﬂy, tosyl-activated
magnetic beads (Dynabeads®; ThermoFisher Scientiﬁc) conjugated
with rhGALNS were washed 3 times in coupling buffer (1× DPBS,
0.01% Tween) and added towells, and the buffer was removed. Samples
diluted 1:2.5 in serum-free RPMI-1640were added to thewellswith the
beads and incubated with shaking at 800 rpm for 1 h. The beads and
samples were separated, and the eluent was tested in the functional
NAb assay (described in Section 2.3).
2.5. Calculations and statistics
Percentage signal inhibition (%SI) was calculated using the equation
%SI= [1− (meanMFI of sample ∕meanMFI of cut-point control)] × 100.
Conﬁrmatory assay data were analyzed as recovery ratio, deﬁned as
mean conﬁrmatory assay MFI of sample∕mean screening assay MFI ofLive Cells MFI Gate 
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Fig. 2. Uptake of Alexa488-rhGALNS by Jurkat cells measured by ﬂow cytometry. (A) Dose-response curve showing uptake (MFI) of Alexa488-rhGALNS (0–363.6 nM). (B) Hanes-Woolf plot between MFI and concentration of Alexa488-rhGALNS.
(C) Uptake of Alexa488-rhGALNS (MFI) following no treatment or treatment of cells with trypan blue, cytochalasin B, or incubation at 4 °C. Error bars (±standard deviation) for each condition are included but may be indistinguishable from the
top of histogram bar. (D) Uptake of Alexa488-rhGALNS (MFI) and Alexa488-anti-CD3 following treatment of cells with 0.005%–0.4% trypan blue. Error bars represent the means ± SDs. (E) Percent signal inhibition (%SI; Alexa488-rhGALNS
uptake MFI relative to non-treated control) following treatment of cells with increasing concentrations of sCI-M6PR, M6P, or goat anti-GALNS antibody.
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44 A.C. Melton et al. / Journal of Immunological Methods 440 (2017) 41–51sample. The titer was calculated as the interpolated dilution factor at
which the sample crossed the titer cut point determined by linear re-
gression analysis (Microsoft Excel).
2.6. Confocal imaging
Internalization of Alexa488-rhGALNS and trafﬁcking to lysosomes
was conﬁrmed by confocal microscopy by incubating cells from the
functional NAb assay described in Section 2.3 with 50 nM LysoTracker
Red (Molecular Probes) at 37 °C for 1 h. Cells were then washed with
serum-free RPMI-1640 and mounted with Prolong Gold Antifade
Mountant with DAPI (Molecular Probes), sealed, and visualized using
a Leica SP8 confocal microscope (Leica Microsystems). Confocal Z-
stacks were acquired using a 63× Plan-Apo objective with 4× zoom
and LASX software (Leica Microsystems). Z-stacks were rendered in 3-
D and exported using Volocity software version 6.3 (PerkinElmer).
3. Results
3.1. Functional NAb assay development
3.1.1. Mechanism of Alexa488-rhGALNS uptake by Jurkat cells
The ﬂow cytometry gating strategy restricted MFI analysis to single,
live Jurkat cells for measurement of Alexa488-rhGALNS uptake (Fig. 1).
To assess optimal rhGALNS uptake conditions by Jurkat cells in vitro, an
Alexa488-rhGALNS dose-response curve was generated (0 to 363.6 nM
or 0 to 40 μg/mL). A dose-dependent increase in MFI was observed in
Jurkat cells incubated with Alexa488-rhGALNS, with a background of
untreated cells detected at an MFI of 43.7 ± 4.7 (Kuptake = 46.3 nM by
Hanes-Woolf plot linear regression analysis; Fig. 2A and B).
To determine if theMFI signal detected after incubation of cells with
Alexa488-rhGALNS resulted from internalized drug or drug bound to
the cell surface, a series of experimentswas conductedwhereby cells in-
cubated with Alexa488-rhGALNS (0.4 μg/mL) in the presence of 20%
pooled human serumwere either placed at 4 °C, quenched with trypan
blue, or treated with cytochalasin B. Cells incubated at 4 °C, which
allowed for drug binding but not uptake, produced an MFI of 92.9 ±
1.50 compared with an MFI of 4425 ± 98.6 when cells were incubated
for the same length of time at 37 °C (Fig. 2C), suggesting that MFI pre-
dominantly measured internalization of Alexa488-rhGALNS. Next,
cells post-incubationwith Alexa488-rhGALNSwere treatedwith trypan
blue, which is impermeable to vital cells, quenches Alexa488 ﬂuores-
cence (Sahlin et al., 1983), and was expected to reduce MFI signals if
Alexa488-rhGALNSwas bound to the cell surface. As a control to ensure
that trypan blue quenched Alexa488 on the surface of Jurkat cells, cells
were labeled with an Alexa488-conjugated mouse monoclonal anti-
body (Clone SP34-2) that binds CD3 expressed on the cell surface of T
cells (Osman et al., 1992). Increasing concentrations of trypan blue re-
duced the ﬂuorescence of cells treated with Alexa488-labeled anti-Lysotracker Red Alexa488-rh
Fig. 3. Alexa488-rhGALNS trafﬁcs to cell lysosomes. Confocal images of ﬁxed Jurkat cells incuba
DAPI nuclear stain (blue) just prior to imaging. Scale bar=5 μm.CD3 (Fig. 2D). However, concentrations of trypan blue up to 0.4% had
no impact on Alexa488-rhGALNS MFI values, suggesting that almost
all of the MFI signal emitted from Alexa488-rhGALNS-treated cells
was the result of drug internalizationwithin cells (Fig. 2C and D). To de-
termine whether drug internalization was a result of endocytosis, cells
were pretreated with cytochalasin B for 1 h prior to incubation with
Alexa488-rhGALNS. MFI signal emitted from Alexa488-rhGALNS-
treated cellswas reduced to 777±4.2MFI in the presence of 374 μMcy-
tochalasin B (Fig. 2C). To conﬁrm the uptake mechanism of Alexa488-
rhGALNS via CI-M6PR, cells were incubated with Alexa488-rhGALNS
in the presence of excess soluble CI-M6PR (sCI-M6PR) or M6P to com-
pete for CI-M6PR binding sites, or an afﬁnity-puriﬁed goat anti-
rhGALNS polyclonal antibody to neutralize rhGALNS binding. Increasing
concentrations of sCI-M6PR, M6P, and anti-rhGALNS antibody dose de-
pendently abrogated Alexa488-rhGALNS uptake (IC50 [μM]= 0.085 for
sCI-M6PR, 452.9 for M6P, and 0.027 for anti-rhGALNS; Fig. 2E). IC50
values for M6P were higher than those for sCI-M6PR or anti-rhGALNS,
likely due to competition with multiple M6P moieties on rhGALNS
and additional proteins containing M6P binding sites. Furthermore,
confocal imaging of Alexa488-rhGALNS-treated cells revealed that
Alexa488-rhGALNS co-localized with lysosomes, conﬁrming that la-
beled rhGALNS is efﬁciently internalized and trafﬁcked to the lysosomes
(Fig. 3). Collectively, these data indicate that internalization of
Alexa488-rhGALNS occurs through M6P-mediated receptor binding to
CI-M6PR followed by endocytosis and trafﬁcking to the lysosome.
3.1.2. Determination of optimal Alexa488-rhGALNS concentration and se-
rum dilution for detection of inhibitory antibodies
A series of dose-response curveswas generated to determine the op-
timal drug dose that would provide detection of approximately 1 μg/mL
afﬁnity-puriﬁed goat anti-rhGALNS polyclonal antibody positive control
(AbPC) in the presence of 20% pooled human serum. Alexa488-
rhGALNS was added to cell media at a ﬁnal concentration of
0.156 μg/mL to 2.50 μg/mL in the presence of increasing concentrations
of AbPC ranging from 0.046 to 100 μg/mL. AbPC interfered with uptake
of Alexa488-rhGALNS in a dose-dependentmanner (Fig. 4A). These data
were then transformed and plotted as the relative fold change over the
maximum concentration of AbPC tested (100 μg/mL; Fig. 4B) to deter-
mine the dose of Alexa488-rhGALNS that would provide a sensitivity
of approximately 1 μg/mL for AbPC. A concentration of 0.313 μg/mL
Alexa488-rhGALNS gave the highest signal-to-noise ratio, and an ap-
proximate maximal SI of 92% was observed in the presence of
11.1 μg/mL AbPC. Together, these data led to the selection of 0.4 μg/mL
Alexa488-rhGALNS for further assay development, including the assay
sensitivity analyses described in Section 3.1.4.
To characterize the potential effect of interference from serum com-
ponents (matrix interference) on detection of NAbs, NPS samples
spiked with AbPC at concentrations ranging from 0.046 to 100 μg/mL
were diluted 2.5-, 5-, 10-, and 20-fold in serum-free media and mixedGALNS Overlay
ted with LysoTracker Red and Alexa488-rhGALNS (green). Cells were counterstained with
Table 1
Receptor binding and cellular uptake NAb assay cut points based on drug-naïve healthy or
target-treatment population samples.
Normal serum Morquio A serum
Cut point type Cell-based
assay
Ligand-binding
assay
Cell-based
assay
Ligand-binding
assay
SCP (%SI) 14.0 14.8 19.6 22.8
CCP (recovery ratio) 1.24 1.05 1.15 1.09
TCP (%SI) 25.8 N/A 30.0 N/A
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Fig. 4.Determination of optimal Alexa488-rhGALNS concentration for detection of inhibitory antibodies. (A) Jurkat cells treatedwith varying concentrations of Alexa488-rhGALNS (0.156–
2.5 μg/mL) premixed with the indicated concentrations of AbPC (anti-rhGALNS). (B) Data from (A) presented as the relative MFI fold change over the MFI from the maximum
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45A.C. Melton et al. / Journal of Immunological Methods 440 (2017) 41–511:1with 0.4 μg/mLAlexa488-rhGALNS. A dilution of 1:2.5 (equivalent to
20% pooled human serum after mixing with Alexa488-rhGALNS)
showed inhibition of Alexa488-rhGALNS uptake at b1 μg/mL and
inhibited uptake at the lowest AbPC concentration relative to the
other dilutions (Fig. 4C). The 1:20 dilution reduced detection of
Alexa488-rhGALNS, even in the absence of inhibition by AbPC
(Fig. 4C). This result indicated that lowNPS concentrations can indepen-
dently reduce drug uptake in this assay, and suggests that factors pres-
ent in human serummay stimulate uptake of Alexa488-rhGALNS by CI-
M6PR in Jurkat cells. Therefore, a minimum required dilution (MRD) of
1:2.5 was chosen to provide optimal sensitivity.
3.1.3. Assay cut points for the cellular uptake NAb assay
A tiered clinical testing strategywas adopted to screen, conﬁrm, and
titer NAb samples that were conﬁrmed positive for binding anti-
elosulfase antibodies (also referred to as total anti-elosulfase antibody,
TAb) (Mire-Sluis et al., 2004). To deﬁne a NAb assay positive/negative
cut point, serum was collected from drug-naïve individuals with
Morquio A syndrome (n= 48) and analyzed in duplicate in 6 separate
experiments performed by 2 analysts over 2 days. At the time of assay
development, serum was unavailable from individuals with Morquio
A syndrome; thus, we used pooled serum from healthy donors without
Morquio A syndrome. The sample %SI data distribution for each runwas
analyzed for normality using the Shapiro-Wilk test (JMP software, SAS
Institute Inc.). Outliers, identiﬁed using box plot analysis (JMP), were
excluded conservatively by removing the minimum number required
to achieve a normal distribution for each run (Shankar et al., 2008).
This approach resulted in normal distributions being established after
exclusion of 2 outliers (0.69%) from the total screening data set. Pooled
variancewas then used to calculate the screening cut point (SCP) based
on the 95th percentile to avoid false-negatives responses, resulting in
an SCP of 14.02% SI. Thus, individual serum samples that reduced signal
by ≥14.02% compared with control serum in the screening step were
considered reactive (potentially positive) during sample testing.
For samples that screened as reactive (potentially positive), a
conﬁrmation step assessed whether the sample signal was increased
by depletion of rhGALNS-speciﬁc antibodies, as would be expected of
true-positive samples. Drug-conjugated beads were used to deplete
rhGALNS-speciﬁc antibodies from serum prior to retesting in the cell-
based assay. A conﬁrmation cut point (CCP) was established by deplet-
ing the same drug-naïve serum samples described above and compar-
ing each with its corresponding non-depleted sample tested on the
same plate. A ﬁxed CCP (recovery ratio of immunodepleted sample
signal/non-depleted sample signal) was determined by ﬁrst evaluating
results from each run for normality and outliers. Lack of normality was
observed in 2 of 6 runs based on the Shapiro-Wilk test (p ≤ 0.05), but the
removal of the minimum number of outliers from the data set (n= 4
[1.41% of data set]) resulted in a normal distribution for all runs
(p ≥ 0.05). Pooled variance was then used to calculate the ﬁxed CCPbased on the 99th percentile of the normal distribution model of the
data, resulting in a recovery ratio CCP of 1.24. Thus, samples that were
reactive in the screening step and had a recovery ratio ≥ 1.24 in the con-
ﬁrmatory step were considered positive during sample testing.
NAb-positive samples were subsequently 3-fold serially diluted
(1:2.5, 1:7.5, 1:22.5, etc.) in a titer experiment to determine relative
NAb levels. A titer cut-point (TCP) of 25.76% SI was calculated based
on the 99.9th percentile of the normal distribution data model de-
scribed for the screening step. To extrapolate a titer value, at least 1 di-
lution of a positive sample had to drop below the TCP.
Once samples from drug-naïve individuals with Morquio A syn-
drome became available from the MOR-004 clinical trial, the screening
and conﬁrmation cut points established during assay validation were
veriﬁed using rawMFI data from 115 baseline and placebo samples col-
lected from 60 drug-naïve individuals with Morquio A syndrome and
tested over 4 months by 4 analysts. Using a similar statistical approach
to the one described above for donors without Morquio A syndrome,
the target treatment population cut points were comparable to the orig-
inal cellular uptake NAb assay cut points derived from non-affected in-
dividuals (Table 1). For the purpose of a concordance assessment
(described in Section 3.2), the cut points of the ELISA-based CI-M6PR
binding assay previously used to detect anti-elosulfase alfa NAb
(Schweighardt et al., 2015) were also conﬁrmed in the 115 baseline
and placebo samples (Table 1). NAb assay concordance using the cut
points from Morquio A individuals was 90% (see Section 3.2),
supporting the use of cut points established with non-affected individ-
uals in the validated assay.
3.1.4. Sensitivity and precision
For detection of neutralizing antibodies elicited by biologic thera-
pies, industry guidelines recommend an assay sensitivity of ≤1 μg/mL
positive control antibody (Gupta et al., 2007). To determine the lowest
concentration of antibody that can be detected in the assay (i.e. sensitiv-
ity or limit of detection [LOD]), AbPC was spiked into NPS at 20 μg/mL
and serially diluted 3-fold to generate an 8-point series (n = 18). For
each dilution series, values crossed the screening cut point with the
%SI signals from at least 2 dilutions ≥ SCP and at least 1 dilution b SCP,
and the mean neat concentration of AbPC was calculated from the
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where serial dilutions crossed the cut point. (C) Representative ﬂow cytometry histograms and Alexa488-rhGALNS MFI for NQC (0 μg/mL), LQC (3 μg/mL), and HQC (20 μg/mL)
samples.
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and correction for theMRD. The sensitivity and LODof the assaywas de-
termined to be 0.97 μg/mL (Fig. 5A).
Once study samples became available, the sensitivity of the method
was conﬁrmed using serum from individuals withMorquio A syndrome
prior to treatment with elosulfase alfa. From 6 dilution curves assayed
over 3 days by a single analyst, a mean value of 0.30 μg/mLwas interpo-
lated at the SCP for samples from individuals withMorquio A (Fig. 5B), a
value similar to the 0.97 μg/mL value obtained during assay validation
using NPS (Fig. 5A).
Assayprecision describes the closeness of replicatemeasurements of
the same sample on the same plate (intra-assay) or between plates
(inter-assay). QC concentrationswere selected to assess assay precision
andmonitor the assayperformance in thepresence of high and low con-
centrations of NAb. AbPC spiked into NPS at 20 μg/mL and 3 μg/mLwere
chosen as high quality control [HQC] and low quality control [LQC] con-
centrations, respectively, based on AbPC performance when serially di-
luted (Fig. 5A). To evaluate assay precision, AbPCwas spiked into NPS at
20 μg/mL (HQC and titer quality control [TQC] concentrations), 3 μg/mL
(LQC concentration) or unspiked (negative quality control [NQC] con-
centration) and the intra-assay and inter-assay coefﬁcient of variation
(CV) was assessed. An example of the raw histogram data for each of
these QC samples is presented in Fig. 5C. The intra- and inter-assay pre-
cisionwas 0.60% and 0.65% CV for theHQC, 12.02% and17.62% CV for the
LQC, 14.88% and 16.50% CV for the NQC, and 12.41% and 28.04% CV for
LQC samples that were conﬁrmed (Table 2). Intra-batch n values vary
slightly between QCs due to differences in the number of QCs tested
on each plate and exclusion of several samples due to instrument mal-
function. Titration of TQC samples showed that 14 of 18 results were
within ±one 3-fold dilution of the median interpolated dilution of
28.54 (data not shown).3.1.5. Speciﬁcity and selectivity
To evaluate the speciﬁcity of rhGALNS neutralization by NAbs in the
uptake assay, samples were prepared by spiking both NPS and
NPS + LQC AbPC with a non-speciﬁc goat IgG−negative control at a
concentration of 3 μg/mL. NPS spiked with only non-speciﬁc goat IgGTable 2
Intra-batch and inter-batch precision of the functional NAb assay. Note the intra-batch “N” is a
Intra-batch (within run) statistics (Pooled)
N (samples) Average SD %CV
% SI
HQC 2.22 96.80 0.58 0.6
LQC 2.26 60.28 7.24 12.02
Median MFI
NQC 2.27 8654.6 1287.6 14.88
Recovery ratio
LQC-C 2.33 3.02 0.37 12.41antibody tested negative in the screening and conﬁrmatory assays.
NPS+LQCAbPC, bothwith andwithout non-speciﬁc goat IgG antibody,
screened and conﬁrmed positive (Table 3), suggesting that the assay is
speciﬁc for anti-rhGALNS antibodies.
To assess effects of serum components on the detection of anti-
rhGALNS in this assay, serum from 10 (5 male/5 female) individual do-
nors aswell as 4 lipemic and 4 hemolyzed sera fromdrug-naïve, healthy
individuals (without Morquio A syndrome) were tested using the
screening assay. To each of these samples, 0 μg/mL (NQC concentration)
or 3 μg/mL (LQC concentration), of AbPC was added to evaluate assay
selectivity. All normal serum samples (10/10) spikedwith LQCwere po-
tentially positive/reactive in the screening step (Fig. 6A). Of the 4
lipemic samples spiked with LQC concentration of AbPC, 1 of 4 (25%)
screened positive, suggesting that there may be interference from
serum lipids in the detection of lower levels of anti-rhGALNS. Converse-
ly, all of the hemolytic samples spikedwith LQC screened positive/reac-
tive, suggesting that hemolysis does not interfere with the detection of
anti-rhGALNS.
Assay selectivity was conﬁrmed in drug-naïve baseline samples from
the MOR-004 study. Selectivity was performed in 10 individual samples
by adding AbPC to the LQC concentration in an aliquot of each sample.
These spiked MOR-004 baseline samples, as well as the corresponding
unspiked serum, were assayed together on a single plate. No matrix
interference was observed using either the healthy or target treatment
population-based SCP. All 10 unspiked samples (100%) screened negative
and all 10 samples (100%) containing LQC AbPC screened positive using
the target population-derived SCP (Fig. 6B).3.1.6. Drug tolerance
The susceptibility of the assay to interference from circulating levels
of drug was evaluated using NPS spiked with or without LQC or HQC
concentrations of the AbPC in the presence of 0 to 2 μg/mL unlabeled
rhGALNS. As expected, LQC and HQC AbPC screened positive in the ab-
sence of unlabeled rhGALNS (Table 4). When low concentrations of un-
labeled rhGALNS (≤0.074 μg/mL) were added to LQC or HQC AbPC, the
%SIs were comparable to those measured in the absence of unlabeled
rhGALNS (Table 4), with slight differences likely due inherent assayn average from runs containing 2 or 3 sets of QCs.
Inter-batch (between run) statistics (ANOVA)
N (samples) Average SD %CV
% SI
67 96.80 0.63 0.65
68 60.74 10.71 17.62
Median MFI
66 8691.7 1434.0 16.5
Recovery ratio
54 3.05 0.85 28.04
Table 3
Evaluation of non-speciﬁc IgG in the functional NAb assay.
LQC Non-speciﬁc IgG %SI %CV Recovery ratio Above SCP Above CCP Result
Screening assay + + 25.54 4.38 N/A Yes N/A Positive
+ − 31.86 9.28 N/A Yes N/A Positive
− + −6.32 9.67 N/A No N/A Negative
− − −1.02 7.18 N/A No N/A Negative
Conﬁrmatory assay + + N/A 2.04 1.42 N/A Yes Positive
+ − N/A 3.46 1.55 N/A Yes Positive
− + N/A 3.87 1.05 N/A No Negative
− − N/A 7.24 1.13 N/A No Negative
47A.C. Melton et al. / Journal of Immunological Methods 440 (2017) 41–51variability. All LQC and HQC AbPC-spiked samples screened positive in
the presence of 2 μg/mL unlabeled rhGALNS. However, concentrations
≥0.22 μg/mL of unlabeled rhGALNS reduced Alexa488-rhGALNS uptake
in NPS without AbPC. These data suggest that unlabeled rhGALNS
inhibited uptake of Alexa488-rhGALNS and indicate that the assay can
tolerate up to 0.22 μg/mL rhGALNS introduced via patient serum.
SinceNAb sampleswere collected from individualswithMorquio A syn-
drome just prior to dosing, when elosulfase alfa has been completely
cleared (Qi et al., 2014), it is unlikely that elosulfase alfa would be pres-
ent in samples at concentrations sufﬁcient to interfere with the assay.
3.2. NAb titers and clinical outcomes
3.2.1. High concordance between functional NAb assay and CI-M6PR bind-
ing assay
To compare the functional NAb assay with the previously reported
ELISA-based CI-M6PR binding assay for detecting NAb in elosulfase
alfa-treated individuals with Morquio A syndrome (Schweighardt
et al., 2015), serum samples from the MOR-004 trial were reanalyzed
with the cell-based assay. Sufﬁcient serum-sample volumes were avail-
able for themajority (842/847 [99%]) of MOR-004 serum sample collec-
tion time points to obtain conﬁrmed positive/negative results. The
overall concordance was high (89%) between NAb positivity in the re-
ceptor binding assay and the cell-based assay. Furthermore, the concor-
dance was consistent over the 24-week treatment period (Fig. 7A).
Concordance between the assays at each study visit week is presented
in Table 5.
TAb titers detected using the CI-M6PR binding assay reported previ-
ously (Schweighardt et al., 2015) were compared to the time course for
NAb titer development detectedwith the functional NAb assay (Fig. 7B).
Titers of both TAbs and NAbs increased rapidly during the ﬁrst 8 weeks-20
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Fig. 6. Interference of matrix on the detection of anti-elosulfase alfa antibodies. %SI data from 5m
serum samples, spikedwith 3 μg/ml anti-rhGALNS (LQC) or unspiked controls. (B) Drug-naïve s
3 μg/mL AbPC (LQC) or unspiked controls. The assay screening cut point of 14.02% in (A) or 19.6%
the means (±standard deviation) of samples tested in 2 independent experiments over 2 dayof treatment then plateaued from week 8 to week 24 in both the QOW
and QW treatment groups (Fig. 7B). Although the frequency of drug ad-
ministration had minimal effect on TAb and NAb titers at week 24, the
QW treatment group appeared to have higher titers of both TAbs and
NAbs in the initial 4 weeks of treatment. Subjects in both the QOW
and QW treatment groups developed different NAb titer courses over
24 weeks (Fig. 7C and D). Titers either initially developed and then
remained relatively constant or gradually declined, or showed an inter-
mittent pattern (Fig. 7C and D).
3.2.2. NAb titers and efﬁcacy responses at week 24
The primary efﬁcacy measure in the MOR-004 study was the dis-
tance walked in a 6MWT, which provides a measure of endurance.
Keratan sulfate, an rhGALNS substrate, was also measured in individ-
uals' urine (uKS) to track the pharmacodynamic effect of treatment
with elosulfase alfa. NAb titers detected with the functional NAb assay
were plotted against the change from baseline toweek 24 in 6MWTdis-
tance, and the percentage change in uKS from baseline. No association
was observed between NAb titer and 6MWT (Fig. 8A) or NAb titer and
uKS (Fig. 8B) in individuals dosed weekly or every 2 weeks. These
data indicate that NAb titers had no detrimental impact on elosulfase
alfa efﬁcacy during the 24-week treatment period.
3.2.3. Effect of NAb titer on elosulfase alfa pharmacokinetics
In order to further explore the association between NAbs and phar-
macokinetics, NAb titers from the functional NAb assay were compared
to total clearance (CL) of drug after intravenous administration and
elimination half-life (t1/2). Increased NAb titers were associated with
prolonged t1/2 in both the QOW and QW cohorts (Fig. 9A). Both cohorts
also displayed a trend toward a correlation between increased NAb-20
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Table 4
Drug tolerance evaluated using NPS-, LQC-, and HQC-spiked samples in the presence of in-
creasing elosulfase alfa concentrations. Entries in bold are interpreted as sample results
that test negative to indicate the concentration of free drug that interferes with detection
of the LQC or HQC samples. Sample results with an asterisk indicate where free elosulfase
alfa directly competes with Alexa488-rhGALNS.
Elosulfase alfa (μg/mL) NHPS (%SI) LQC (%SI) HQC (%SI)
2.00 55.42* 53.63* 22.90
0.67 26.94* 16.72 95.08
0.22 8.00 23.21 95.35
0.074 −5.58 50.70 95.76
0.025 −7.21 66.34 95.47
0.008 3.79 69.97 95.26
0.0027 −10.84 61.71 95.26
0 −13.25 61.34 95.02
48 A.C. Melton et al. / Journal of Immunological Methods 440 (2017) 41–51titers and decreased CL (Fig. 9B). Together these results suggest that
NAbs may slow the clearance of elosulfase alfa from plasma.
4. Discussion
Many approved and investigational ERTs for lysosomal storage dis-
eases trafﬁc drugs from the extracellular space to lysosomes by using
CI-M6PR, a transmembrane receptor with binding sites for M6P and
IGF-2. Immunogenicity is a concern with biologic therapies, and NAb
generated against an ERT may inﬂuence therapeutic outcomes (Brooks
et al., 2003; Desnick & Schuchman, 2012; Banugaria et al., 2011;0
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Fig. 7. NAb assay concordance and titers in individuals treated with elosulfase alfa in the MOR
binding assay and the cell-based functional NAb assay in samples from individuals treated wit
and NAb titer (from cell-based functional NAb assay) over 24 weeks in samples from individu
Individual NAb titers from subjects in the 2.0 mg/kg QOW (C) or 2.0 mg/kg QW (D) elosulfaseDvorak-Ewell et al., 2010). NAbs that block enzyme activity may also
develop, although many ERTs, including elosulfase alfa, are not enzy-
matically active in the neutral pH of blood. Therefore, generation of
NAbs that directly inhibit ERT activity has not been a primary concern
in studies of ERTs (Brooks et al., 2003; Desnick & Schuchman, 2012) be-
cause the low pH and proteolytic environment of the lysosome is likely
to dissociate and/or degrade antibodies. Instead, the focus of our surveil-
lance was assessing the capacity of antibodies to interfere with cellular
uptake of elosulfase alfa.
In this study, we analyzedMOR-004 serum samples using a validated
cell-basedNAbﬂowcytometry assaywith a titer step. Comparedwith the
previously used CI-M6PR binding assay, the format of this cell-based
assay measures interference with cellular uptake of elosulfase alfa. This
assay format was anticipated to demonstrate greater physiological
relevance to the in situ environment due to the interaction of NAb-drug
complexes with functional CI-M6PR on living human cells. In contrast,
our previously reported in vitro CI-M6PR binding assay measures the
interaction of biotin-labeled rhGALNS with bovine-derived CI-M6PR
immobilized on an ELISA plate (Schweighardt et al., 2015). For the func-
tional NAb assay, human T-cell lymphoma Jurkat cells were selected for
their native expression of CI-M6PR, which is also expressed on primary
human T cells (Wood & Hulett, 2008; Motyka et al., 2000).
Several experiments in the present study support the in vivo rele-
vance of this assay format. Experiments with cytochalasin B, trypan
blue, and incubation of cells at 4 °C indicate that nearly all Alexa488-
rhGALNS ﬂuorescence signal resulted from internalized drug (i.e. drug4 8 12 16 20 24
Study Visit (Week)
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-004 study. (A) Concordance between NAb positivity detected with the in vitro CI-M6PR
h placebo, elosulfase alfa 2.0 mg/kg QOW, or elosulfase alfa 2.0 mg/kg QW. (B) Mean TAb
als treated with placebo, elosulfase alfa 2.0 mg/kg QOW, or elosulfase alfa 2.0 mg/kg QW.
alfa treatment groups over 24 weeks.
Table 5
Concordance of NAb assay results by study week. Ligand receptor binding NAb and cell-based uptake NAb assay positive (+) and negative (−) values are shown with percentages in
parentheses.
Treatment group Study week
Receptor binding (−) Receptor binding (+) Receptor binding (−) Receptor binding (+)
Cellular uptake (−) Cellular uptake (+) Cellular uptake (+) Cellular uptake (−)
Placebo Baseline 59(100.0)
2 59(100.0)
4 58(100.0)
8 57(100.0)
12 56(94.9) 1(1.7) 2(3.4)
16 57(96.6) 2(3.4)
20 58(98.3) 1(1.7)
24 57(96.6) 2(3.4)
2.0 mg/kg/QOW Baseline 59(100.0)
2 54(93.1) 1(1.7) 3(5.2)
4 47(79.7) 7(11.9) 5(8.5)
8 14(23.7) 40(67.8) 3(5.1) 2(3.4)
12 7(12.1) 43(74.1) 3(5.2) 5(8.6)
16 9(15.5) 42(72.4) 7(12.1)
20 5(8.5) 44(74.6) 3(5.1) 7(11.9)
24 8(14.0) 41(71.9) 2(3.5) 6(10.5)
2.0 mg/kg/QW Baseline 57(98.3) 1(1.7)
2 45(80.4) 4(7.1) 4(7.1) 3(5.4)
4 12(21.4) 39(69.6) 1(1.8) 4(7.1)
8 2(3.6) 47(85.5) 3(5.5) 3(5.5)
12 3(5.6) 47(87.0) 4(7.4)
16 2(3.6) 49(87.5) 5(8.9)
20 3(5.3) 46(80.7) 1(1.8) 7(12.3)
24 6(11.1) 43(79.6) 1(1.9) 4(7.4)
49A.C. Melton et al. / Journal of Immunological Methods 440 (2017) 41–51not bound to the cell surface). Confocal imaging of cells incubated with
Alexa488-rhGALNS and LysoTracker Red, a lysosome-speciﬁc pH-
sensitive dye, demonstrated that the drug was trafﬁcked to the lyso-
somewithin the timeframe of the assay. Internalization by CI-M6PR ap-
pears to be the sole mechanism of Alexa488-rhGALNS entry in Jurkat
cells, because competition with sCI-M6PR or M6P completely blocked
Alexa488-rhGALNS uptake. Because most ERTs trafﬁc to lysosomes via
CI-M6PR, this assay platform has the potential for broad application in
the study of NAbs to ERTs.
Serum samples collected from individuals with Morquio A syn-
drome who received elosulfase alfa intravenously at 2.0 mg/kg QOW
or QW in the MOR-004 phase 3 clinical study were previously assessed
as positive or negative for neutralizing antibodies, without titers, using
an in vitro CI-M6PR binding ELISA assay (Schweighardt et al., 2015).
Despite the differences between this in vitro assay format and the cell-
based format presented here, results were highly concordant with
N89% testing either positive or negative in both assays. Preliminary
analysis of the minority of samples that differed between the assaysA
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cohorts.showed that the results of ≥90% of discordant samples were within
30% of the SCP, CCP, or both. Therefore, at least some of the discordant
data may be attributable to analytical variability associated with testing
samples with relatively low positivity.
An analysis of the potential impacts of NAb on efﬁcacy was per-
formed using the percentage of study visits with a positive NAb result.
Conﬁrming previous results (Schweighardt et al., 2015), no associations
were found between the number of occasions an individual tested pos-
itive for receptor binding NAb and changes in efﬁcacy responses from
baseline to week 24 in 6MWT distance or changes in the pharmacody-
namic marker uKS. NAb titers derived from the new cell-based assay
were also not correlated with efﬁcacy outcomes in either dose group,
measured by changes in 6MWT or uKS from baseline to week 24. We
previously reported that NAb positivity, but not TAb titer, was associat-
edwith a decreased rate of CL from serum and prolonged t1/2 in individ-
uals receiving a weekly dose of elosulfase alfa (Qi et al., 2014). In
this study, we found that increased NAb titers also correlated with
decreased plasma clearance rates and increased t1/2 compared with1 10 100 1000 10000
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Fig. 9. NAb titer correlation with elosulfase alfa half-life and clearance in individuals in the MOR-004 study. (A) Serum half-life (t1/2; min) of elosulfase alfa at week 22 is plotted against
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50 A.C. Melton et al. / Journal of Immunological Methods 440 (2017) 41–51lower NAb titers. However, higher NAb titerswere not associatedwith a
less robust pharmacodynamic effect, as measured by change in uKS
levels from baseline to week 24. Results from a neutralizing antibody
assay would ideally correlate with an effect on drug efﬁcacy that could
inform physicians of a developing immune response that would impact
the patient's ability to beneﬁt from the drug. While this study was de-
signed to monitor antibodies that neutralize cellular uptake of drug, it
is possible that an immune response to elosulfase alfa may develop in
some individuals that exerts biological effects not measured in this
assay. Future work on neutralizing antibody assays to ERTs should con-
tinue to be reﬁned so that all circumstances are monitored for identify-
ing antibodies capable of neutralizing the clinical effect of the drug.
Our ﬁnding that NAb titers had no correlationwith elosulfase alfa ef-
ﬁcacy contributes to an emerging body of work on the relationship be-
tween ERT immunogenicity and drug activity (Banugaria et al., 2011;
Benichou et al., 2009; Brands et al., 2013; Jameson et al., 2013). The
bulk of publications on this topic come from studies on the immunoge-
nicity of patients with infantile-onset Pompe disease following treat-
ment with alglucosidase alfa. Patients with Pompe disease may be
classiﬁed as either positive or negative for cross-reactive immunological
material (CRIM), depending on whether they express immunologically
detectable levels of acid alpha-glucosidase protein. A negative CRIM sta-
tus has been reported to correlatewith higher antibody titers andworse
therapeutic outcomes (Kishnani et al., 2010); however, one recent
study of 11 patients showed no correlation between antidrug antibody
titers and CRIM status (van Gelder et al., 2013). Another study of pa-
tients with MPS II (Hunter syndrome) treated with idursulfase found
that those with nonsense or frameshift mutations were more likely to
develop antibodies to idursulfase, but antibody positivity had no associ-
ation with improvements in the 6MWT distance, percent predicted
forced vital capacity, or liver and spleen volume (Barbier et al., 2013).
Although the CRIM status of individuals with Morquio A syndrome
was not assessed in theMOR-004 study, the lack of any relationship be-
tween antibody positivity, antibody type (total antibodies vs neutraliz-
ing), or antibody titers with efﬁcacy outcomes indicates that elosulfase
alfa maintains therapeutic activity in the presence of an antibody re-
sponse. Subjects may also develop immunologic tolerance to repeated
dosing of elosulfase alfa. Indeed, for subjects participating in the MOR-
005 long-term extension study, the proportion of patients with NAb
positivity decreased between week 36 and week 120 (Long et al.,
submitted for publication.).
Antibodies that neutralize elosulfase alfa uptake through CI-M6PR
may not exist at concentrations sufﬁcient to prevent effective amounts
of elosulfase alfa from reaching target tissues. Although NAbs that
block uptake of drug are measureable in our cell-based NAb assay, this
amount of NAbs may be insigniﬁcant relative to elosulfase alfa dose.This cell-based assay was designed to detect the lowest possible NAb
concentrations, ideally prior to observed clinical effects. Of note, the plas-
ma Cmax for elosulfase alfa (4.0 μg/mL for 2.0 mg/kg QW and 2.6 μg/mL
for 2.0 mg/kg QOW groups after 22 weeks) is much higher than concen-
trations used in the assay (0.4 μg/mL Alexa488-labeled elosulfase alfa)
(Qi et al., 2014). While the titer and afﬁnity of the assay positive control
antibody may not be comparable to the antibody response in study sub-
jects, the low and stable titers (mean titer = 118 ± 271 at 12 weeks)
support the hypothesis that NAbs may not be present in sufﬁcient quan-
tities to impact elosulfase alfa efﬁcacy.Moreover, elosulfase alfa is rapidly
taken into cells and is cleared from plasma with a half-life (t1/2) of 19 or
36 min for the 2.0 mg/kg QOW or 2.0 mg/kg QW groups after 22 weeks,
respectively (Qi et al., 2014). Although further investigation is needed,
one aspect to the lack of neutralizing antibody effect on efﬁcacy may
be that rapid clearance of drug from plasma diminishes the rate of neu-
tralizing antibody-elosulfase alfa complex formation. For other biologic
therapies where NAb have been shown to impact efﬁcacy, such as
interferon-β for treatment of multiple sclerosis, administration of higher
concentrations of drug has been shown to overcome NAb and restore ef-
ﬁcacy (Millonig et al., 2009).
Another possible explanation for the lack of correlation between
NAbs and efﬁcacy is that elosulfase alfa may be taken up as NAb-drug
complexes through binding of the Fc portion of NAbs by Fc receptor-
expressing cells independently of CI-M6PR. The role of Fc receptor-
expressing cells, such as monocytes and macrophages, in Morquio A
syndrome is poorly understood, although it is possible these cells partic-
ipate in the clearance or regulation of GAG (Dvorak-Ewell et al., 2010).
Uptake of elosulfase alfa through NAb complexes could result in GAG
clearance within these cell types or otherwise improve the function of
these cells previously impaired by accumulated GAG. Further investiga-
tion into the role of Fc receptor-expressing cells inMorquio A syndrome
will shed light on this possibility.
5. Conclusion
The development of a novel cell-based functional assay for analyzing
the inhibition of elosulfase alfa receptor binding and internalization
conﬁrmed the presence of lowNAb titers in the serum of 98% of individ-
uals with Morquio A syndrome treated with elosulfase alfa. The pres-
ence of NAbs at these titers was insufﬁcient to negatively impact
efﬁcacy or pharmacodynamic effects observed in the MOR-004 study.
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